- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/64 - Relaxins
Patent holdings for IPC class C07K 14/64
Total number of patents in this class: 115
10-year publication summary
|
8
|
10
|
11
|
15
|
7
|
11
|
8
|
12
|
11
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Ambrx, Inc. | 181 |
14 |
| Bristol-myers Squibb Company | 4879 |
9 |
| MedImmune Limited | 614 |
9 |
| Sanofi | 4036 |
9 |
| The Scripps Research Institute | 1347 |
8 |
| Immatics Biotechnologies GmbH | 1155 |
5 |
| Modernatx, Inc. | 1263 |
5 |
| Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | 9 |
5 |
| Chemical & Biopharmaceutical Laboratories of Patras S.A. | 28 |
4 |
| Florey Institute of Neuroscience and Mental Health | 42 |
4 |
| Eli Lilly and Company | 3832 |
3 |
| Howard Florey Institute of Experimental Physiology and Medicine | 17 |
3 |
| River 2 Renal Corp. | 3 |
3 |
| Tectonic Operating Company, Inc. | 5 |
3 |
| Bayer Intellectual Property GmbH | 2509 |
2 |
| Adaptimmune Limited | 188 |
2 |
| National University of Singapore | 2436 |
2 |
| Tectonic Therapeutic, Inc. | 4 |
2 |
| F. Hoffmann-La Roche AG | 7934 |
1 |
| AstraZeneca AB | 2928 |
1 |
| Other owners | 21 |